Why Is Hims & Hers Health Stock Surging on Thursday?

Benzinga07-24

Hims & Hers Health Inc (NYSE:HIMS) stock traded higher on Thursday after an Food and Drug Administration advisory panel voted to place the BPC-157 peptide on an allowed pharmacy compounding list. The...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2653771213?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/cdn-cgi/image/width=3840,format=auto,quality=85/files/images/story/2026/07/23/Hims--Hers-Health-Inc.jpg","is_english":true,"pubTime":"2026-07-24 02:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2653771213","market":"us","top_or_hot":-1,"title":"Why Is Hims & Hers Health Stock Surging on Thursday?","media":"Benzinga","content":"<div>\n<p>Hims & Hers Health Inc (NYSE:HIMS) stock traded higher on Thursday after an Food and Drug Administration advisory panel voted to place the BPC-157 peptide on an allowed pharmacy compounding list. \nThe...</p>\n\n<a href=\"https://www.benzinga.com/trading-ideas/movers/26/07/60651683/why-is-hims-hers-health-stock-surging-on-thursday\">Source Link</a>\n\n</div>\n","source":"benzinga_hot_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Is Hims & Hers Health Stock Surging on Thursday?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Is Hims & Hers Health Stock Surging on Thursday?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-24 02:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/trading-ideas/movers/26/07/60651683/why-is-hims-hers-health-stock-surging-on-thursday><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Hims & Hers Health Inc (NYSE:HIMS) stock traded higher on Thursday after an Food and Drug Administration advisory panel voted to place the BPC-157 peptide on an allowed pharmacy compounding list. \nThe...</p>\n\n<a href=\"https://www.benzinga.com/trading-ideas/movers/26/07/60651683/why-is-hims-hers-health-stock-surging-on-thursday\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HEAL","symbol_name":"Global X HealthTech ETF","start_time":0,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/07/60651683/why-is-hims-hers-health-stock-surging-on-thursday","article_id":"2653771213","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/cdn-cgi/image/width=3840,format=auto,quality=85/files/images/story/2026/07/23/Hims--Hers-Health-Inc.jpg"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/trading-ideas/movers/26/07/60651683/why-is-hims-hers-health-stock-surging-on-thursday","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2653771213","pubTimestamp":1784831640,"columns":[],"sourceInfo":{"source_id":"benzinga_hot_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Hims & Hers Health Inc (NYSE: HIMS) stock surges Thursday after an FDA advisory committee votes on adding BPC-157 to the allowed pharmacy compounding list.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"HEAL":"Global X HealthTech ETF","BK4196":"保健护理服务","THNR":"AMPLIFY WEIGHT LOSS DRUG & TREATMENT ETF","HIMS":"Hims & Hers Health Inc.","HMYY":"GraniteShares YieldBoost HIMS ETF","HIMY":"Defiance Leveraged Long + Income HIMS ETF","GLAM":"Corgi Beauty, Skincare & Aesthetics ETF","HIYY":"YieldMax HIMS Option Income Strategy ETF","HIMZ":"DEFIANCE DAILY TARGET 2X LONG HIMS ETF"},"translate_title":"为什么 Hims & Hers Health 股票周四飙升？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HMYY":0.6,"HIYY":0.6,"HIMZ":0.6,"HIMS":1.97,"HIMY":0.6,"GLAM":0.6,"THNR":0.6,"HEAL":0.6},"content_text":"Hims & Hers Health Inc (NYSE:HIMS) stock traded higher on Thursday after an Food and Drug Administration advisory panel voted to place the BPC-157 peptide on an allowed pharmacy compounding list. \nThe Nasdaq is down 1.96% while the S&P 500 has shed 1.32%, and HIMS is also outperforming a Healthcare sector that’s up 0.87%.\nThe price movement follows a decision by the Pharmacy Compounding Advisory Committee (PCAC) during its scheduled July 23–24 meetings regarding bulk lists under the 503A framework. \nUnder this regulatory framework, inclusion on the 503A Bulk List allows state-licensed pharmacies to compound reviewed peptides.\nEarlier in July, BofA Securities analyst Allen Lutz noted that preliminary FDA briefing materials had recommended against adding seven peptides to the list, citing concerns over limited clinical evidence, unresolved safety and quality questions and insufficient support for proposed use cases. \nHowever, Lutz noted that the FDA’s preliminary position required advisory panel input before any final determination.\nShort interest in Hims & Hers Health decreased during the latest reporting period, falling from 65.47 million to 61.17 million. This drop leaves 31.82% of the company’s publicly available stock short. \nBased on a recent average daily volume of 18.92 million shares, it would take 3.23 days for holders of this short interest to close out their positions without sending the stock sharply higher.\nHims & Hers Health will report second quarter earnings on August 10. Consensus estimates project earnings per share of -$0.04 alongside quarterly revenue of $724.14 million.\nRecent analyst actions include BofA Securities maintaining a Neutral rating while raising its price forecast to $37 on July 9, and Canaccord Genuity maintaining a Buy rating while raising its forecast to $40 on July 1.\nHIMS is now trading 0.6% above its 20-day SMA ($34.74) and 15.4% above its 50-day SMA ($30.28), which keeps the intermediate trend pointed up after the recent swing low in May. It’s also 12% above the 200-day SMA ($31.20), a constructive sign for trend followers watching whether the stock can hold above longer-term trend gauges.\nMomentum looks more reset than stretched, with RSI at 54.63, which signals neutral conditions rather than an overbought chase. The moving-average structure is mixed: the 20-day SMA is above the 50-day SMA (bullish), but the 50-day SMA remains below the 200-day SMA, reflecting the lingering \"death cross\" that formed in December.\nHIMS Price Action: Hims & Hers Health shares were up 5.68% at $33.47 at the time of publication on Thursday, according to Benzinga Pro data.\nPhoto: Lori Butcher / Shutterstock\nThis content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.\nTo add Benzinga News as your preferred source on Google, click here.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2653771213","isCrawlerRequest":true}